Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nezam H Afdhal

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Hepatology (Baltimore, Md.)|October 18, 2021
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitisArun J Sanyal, Quentin M Anstee, Michael Trauner, et al.
Gastroenterology|October 16, 2013
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapyNezam H Afdhal, Geoffrey M Dusheiko, Edoardo G Giannini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 27, 2022
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis BMan-Fung Yuen, Chi-Yi Chen, Chun-Jen Liu, et al.
Gastroenterology|July 11, 2018
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic SteatohepatitisStephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, et al.
Journal of Hepatology|October 7, 2018
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertibSaumya Jayakumar, Michael S Middleton, Eric J Lawitz, et al.
Hepatology (Baltimore, Md.)|July 5, 2019
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR TrialsQuentin M Anstee, Eric J Lawitz, Naim Alkhouri, et al.
Gastroenterology|August 9, 2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trialFred Poordad, Eric Lawitz, K Rajender Reddy, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
Journal of Hepatology|June 28, 2011
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patientsAlexander J Thompson, Paul J Clark, Abanish Singh, et al.
Gastroenterology|April 20, 2010
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusAlexander J Thompson, Andrew J Muir, Mark S Sulkowski, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Hepatology (Baltimore, Md.)|October 18, 2021
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitisArun J Sanyal, Quentin M Anstee, Michael Trauner, et al.
Gastroenterology|October 16, 2013
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapyNezam H Afdhal, Geoffrey M Dusheiko, Edoardo G Giannini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 27, 2022
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis BMan-Fung Yuen, Chi-Yi Chen, Chun-Jen Liu, et al.
Gastroenterology|July 11, 2018
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic SteatohepatitisStephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, et al.
Journal of Hepatology|October 7, 2018
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertibSaumya Jayakumar, Michael S Middleton, Eric J Lawitz, et al.
Hepatology (Baltimore, Md.)|July 5, 2019
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR TrialsQuentin M Anstee, Eric J Lawitz, Naim Alkhouri, et al.
Gastroenterology|August 9, 2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trialFred Poordad, Eric Lawitz, K Rajender Reddy, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
Journal of Hepatology|June 28, 2011
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patientsAlexander J Thompson, Paul J Clark, Abanish Singh, et al.
Gastroenterology|April 20, 2010
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusAlexander J Thompson, Andrew J Muir, Mark S Sulkowski, et al.
Pageof 12